智通财经APP获悉,BlissBio Inc.(简称:百力司康)于6月29日递交的港股招股书满6个月,于12月29日失效,递表时高盛、华泰国际及建银国际为联席保荐人。

招股书显示,百力司康是一家处于临床阶段的生物制药公司,致力于开发下一代抗体偶联药物(ADC),以解决目前肿瘤治疗中重要的未满足的需求。公司核心产品BB-1701(核心产品)是一种人类表皮生长因子受体2(HER2)靶向型艾立布林ADC候选药物,主要针对乳腺癌(BC)、非小细胞肺癌(NSCLC)和潜在的其他HER2表达癌症。
智通财经APP获悉,BlissBio Inc.(简称:百力司康)于6月29日递交的港股招股书满6个月,于12月29日失效,递表时高盛、华泰国际及建银国际为联席保荐人。

招股书显示,百力司康是一家处于临床阶段的生物制药公司,致力于开发下一代抗体偶联药物(ADC),以解决目前肿瘤治疗中重要的未满足的需求。公司核心产品BB-1701(核心产品)是一种人类表皮生长因子受体2(HER2)靶向型艾立布林ADC候选药物,主要针对乳腺癌(BC)、非小细胞肺癌(NSCLC)和潜在的其他HER2表达癌症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.